Parallel Advisors LLC Sells 1,326 Shares of Sanofi (NASDAQ:SNY)

Parallel Advisors LLC trimmed its position in shares of Sanofi (NASDAQ:SNY) by 15.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,425 shares of the company’s stock after selling 1,326 shares during the quarter. Parallel Advisors LLC’s holdings in Sanofi were worth $358,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Synergy Asset Management LLC acquired a new stake in Sanofi in the fourth quarter valued at $25,000. McClarren Financial Advisors Inc. grew its position in shares of Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after buying an additional 543 shares during the last quarter. Sunbelt Securities Inc. increased its stake in shares of Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after buying an additional 313 shares during the period. Sierra Ocean LLC bought a new position in shares of Sanofi during the fourth quarter worth about $44,000. Finally, Versant Capital Management Inc acquired a new position in shares of Sanofi in the fourth quarter worth approximately $54,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Stock Down 1.5 %

Sanofi stock opened at $56.90 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $144.40 billion, a PE ratio of 22.85, a PEG ratio of 1.01 and a beta of 0.58. The firm’s fifty day moving average is $54.55 and its 200 day moving average is $52.93. Sanofi has a 12-month low of $45.22 and a 12-month high of $60.12.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, sell-side analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. The Goldman Sachs Group began coverage on shares of Sanofi in a research report on Friday. They set a “neutral” rating and a $65.00 price target on the stock. Finally, Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $62.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.